CombiGene’s senior executives are the Company’s CEO Jan Nilsson, the Company’s Chief Research and Development Officer Karin Agerman and Anna Jönsson, Chief Financial Officer. The senior executives are listed below with information about year of birth, when they took office, experience, current and previous assignments over the last five years, holdings in other companies in which they are active and holdings in the Company. “Holdings in the Company” refer to own and/or related parties’ holdings.
Jan Nilsson, CEO
CEO since 2016. (Born 1949)
Education and experience: Jan Nilsson has an MA from the University of Gothenburg and an MBA from Uppsala University. Jan was appointed CEO of CombiGene on 1 October 2016. He has long-standing experience from large pharmaceutical companies and biotech firms. He has also been active in several different areas in the pharmaceutical industry such as pharmaceuticals development and the launch, sales and marketing of established international brands. He also has a solid management background, having served as CEO of both private and public-sector companies.
Current assignments: Board member of CanImGuide Therapeutics AB, Urbicum Ledningskonsult AB and Panion Animal Health.
Previous assignments: CEO of NeuroVive Pharmaceutical AB.
Owner and active in the following companies: Urbicum Ledningskonsult AB.
Own and/or related parties’ holdings in the Company: 500 000 shares. Warrants TO3 127 760, Warrants TO€ 127 760.
Karin Agerman, Chief Research and Development Officer
Chief Research and Development Officer since 2018. (Born 1973)
Education and experience: Karin Agerman has a PhD in molecular neurobiology from Karolinska Institutet and more than fifteen years of experience in the international pharmaceutical industry and the start-up arena in Sweden. She has worked for such companies as AstraZeneca, Merck and Uppsala BIO, and has been active in a number of senior positions. Areas in which she has been active include preclinical development, marketing and financing. Her contact network is broad in both industry and academia, as well as in the sphere of Swedish government agencies.
No current assignments.
No previous assignments over the last five years.
She has been neither owner nor active in any companies over the last five years.
Own and/or related parties’ holdings in the Company: No holdings in shares or warrants.
Anna Jönsson, Chief Financial Officer
Chief Financial Officer since 2019. (born 1984)
Education and experience: Anna Jönsson has a degree in economics and accounting from the IHM Business School and has close to ten years’ experience in the accounting and auditing industry.
She has worked as a qualified accounting consultant and office manager in Lund at Resursgruppen Ekonomi & Revision AB, where she was also a member of the management team. Anna has extensive experience with research and development companies, both listed on regulated markets and unlisted. Her role as a consultant has involved responsibility for finance and accounting at several companies.
Current assignments: Employed at Fåhraeus Institute AB. Responsible for book-keeping, annual accounts and financial reporting for Respiratorius AB (publ.) as well as Longboat Amniotics AB.
Owner and active in the following companies during the last five years: Resursgruppen Ekonomi & Revision AB
Own and/or related parties’ holdings in the Company: No holdings of shares or warrants.
Annika Ericsson, Senior Project Manager
Annika Ericsson, Senior Project Manager since Dec. 2018. (Born 1974)
Education and experience: Annika Ericsson holds a PhD in medical biochemistry from Karolinska Institutet. Her thesis topic concerned enzyme and gene therapy for acute intermittent porphyria. She has postdoc experience from Mount Sinai School of Medicine in New York and 14 years of experience in the biotech industry, having worked with Zymenex A/S and Chiesi. She has worked with lab and development work and upscaling of the production process for protein drugs, and has worked as project manager for preclinical studies of lysosomal storage disorders. Annika has broad experience of planning, organizing and conducting large research projects.
Daniela Morath, Corporate Administration
Daniela Morath, Corporate Administration since 2018. (Born 1980)
Education and experience: Daniela Morath has completed a natural sciences programme and has a higher vocational education diploma in 3D printing. She has several years of experience of administrative duties in various industries and has also worked for a couple of years with business administration and salary administration. Daniela has worked both in larger companies in the industry sector and in smaller service-oriented companies, which has given her experience of different administrative processes.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.